Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia

European Journal of Haematology
J R NovotnyU Dührsen

Abstract

The possible contribution of surface molecules to the development of leukostasis syndrome in hyperleukocytic acute myeloid leukaemia (AML) was assessed by routine immunophenotyping and grading of the probability of clinical leukostasis. Fifty-three patients (23 women, 30 men, median age 59 yr) with hyperleukocytic AML [white blood count (WBC) above 50 x 10(9)/L] were graded for the probability of clinical leukostasis according to the severity of neurologic, pulmonary and other symptoms possibly caused by leukostasis using a recently published scoring system. Age, WBC, absolute blast count, haemoglobin, cytogenetic risk group, infection, relative CD56 expression and absolute count of CD56 positive blasts were analyzed in multivariate stepwise backward logistic regression analysis. In patients with acute monocytic leukaemia (AML M4/M5) the absolute count of leukaemic blasts expressing CD56/NCAM was highly associated with the development of symptoms graded as highly probable leukostasis and all three patients succumbing to early death were CD56 positive. Only the absolute count of CD56 positive blasts was a significant predictor of risk of severe leukostasis (P = 0.020). This was not found in AML without monocytic involvement (AML...Continue Reading

References

Jun 1, 1992·Leukemia Research·Y IizukaT Horie
Jan 1, 1988·American Journal of Hematology·G J VenturaM J Keating
Feb 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·L K Needham, R L Schnaar
Apr 3, 1999·Journal of Cutaneous Pathology·H KuwabaraK Kawakami
Jul 10, 2001·British Journal of Haematology·S MustjokiA Vaheri
Mar 12, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Pierluigi PorcuMichael Bissell
Dec 13, 2003·Leukemia·M C BénéUNKNOWN EGIL, European Group on Immunological Classification of Leukemias
Apr 2, 2004·International Journal of Clinical Practice·N TiftikE Muftuoglu
Jan 25, 2005·Neurochemical Research·Peter S WalmodElisabeth Bock

❮ Previous
Next ❯

Citations

Feb 19, 2014·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Kuan-Hao ChenTing-Chi Yeh
Apr 3, 2012·Hematology/oncology Clinics of North America·Jan Cerny, Alan G Rosmarin
Jul 9, 2010·Revue des maladies respiratoires·Y UzunhanA Bergeron
Dec 17, 2014·Cancer Control : Journal of the Moffitt Cancer Center·Laura S Connelly-Smith, Michael L Linenberger
Feb 3, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Olga K WeinbergRobert P Hasserjian
Jun 15, 2010·Journal of the American Academy of Dermatology·Cynthia M MagroA Neil Crowson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.